VINEET LABORATORIES LTD is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 243 | 191 | 212 | 151 | 75 |
| EBITDA (ex other income) | 8 | 13 | 8 | 7 | (16) |
| margin % | 3.3 | 6.9 | 3.6 | 4.8 | (21.7) |
| Owners' profit | 2 | 7 | 1 | 1 | (20) |
| EPS, as reported (₹) | 2.18 | 7.16 | 1.36 | 1.11 | (21.90) |
| ROE % · ROCE % | 6.7 · 19.7 | 20.0 · 29.9 | 3.7 · 13.1 | 3.0 · 12.6 | (137.8) · (83.4) |
| Debt / equity (x) | 0.47 | 0.80 | 0.92 | 1.28 | 2.73 |
| Cash from operations | (9) | 8 | (10) | (11) | 11 |
| Capex | (8) | (4) | (8) | (0) | (1) |
| ₹ crore | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37 | 24 | 19 | 18 | 14 | 7 | 17 | 16 |
| Profit before tax | 1 | (2) | (2) | (6) | (11) | (1) | 0 | 1 |
| Net profit | 2 | (2) | (2) | (6) | (11) | (1) | 0 | 1 |
| EPS (₹) | 2.09 | (2.31) | (1.98) | (6.19) | (11.42) | (0.94) | 0.43 | 0.92 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · NSE seeks clarification on missing June 2026 quarter results | regulatory legal | high | — | — |
| 29 Aug 2026 · Audited FY26 Results: Revenue Down 21%, PAT Turns Positive at Rs 1.11 Cr | results | high | — | — |
| 25 Aug 2026 · Vineet Labs FY26: turns to Rs 111 lakh profit from Rs 20 crore loss | results | high | — | — |
| 25 Aug 2026 · Board approves FY26 audited results, unqualified opinion | results | high | — | — |
| 20 Aug 2026 · Board meeting on Aug 25 to approve Q4 and FY26 audited results | results | low | — | — |
| 30 Jul 2026 · RTA compliance certificate under SEBI regulation 74(5) filed for Q1 FY27 | compliance | minimal | — | — |
| 21 Jul 2026 · Promoter MD steps down, continues as Non-Executive Director | management changes | high | — | — |
| 21 Jul 2026 · Rajesh Kumar Kathulla appointed as Executive Director at Vineet Laboratories | management changes | high | — | — |
| 16 Jul 2026 · Board Meeting deferred; audited FY26 results approval postponed | board shareholder meetings | medium | — | — |
| 11 Jul 2026 · Board meeting on 15 July 2026 to approve Q4 and FY26 audited results | results | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
